Cardiovascular event reduction among a US population eligible for semaglutide per the SELECT trial

Our objective was to determine the number of major cardiovascular events (MACE, nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death) and deaths from any cause that could be prevented across varying nationwide uptake of semaglutide 2.4 mg SC weekly for the secondary prevention of...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The American heart journal 2024-10, Vol.276, p.110-114
Hauptverfasser: Lusk, Jay B., Glover, LáShauntá, Soneji, Samir, Granger, Christopher B., O'Brien, Emily, Pagidipati, Neha
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 114
container_issue
container_start_page 110
container_title The American heart journal
container_volume 276
creator Lusk, Jay B.
Glover, LáShauntá
Soneji, Samir
Granger, Christopher B.
O'Brien, Emily
Pagidipati, Neha
description Our objective was to determine the number of major cardiovascular events (MACE, nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death) and deaths from any cause that could be prevented across varying nationwide uptake of semaglutide 2.4 mg SC weekly for the secondary prevention of cardiovascular disease. Using a nationally representative cross-sectional study of participants in the 2017-2018 and 2019-March 2020 cycles of the National Health and Nutrition Examination Survey in the U.S. (NHANES), we estimated the number of MACE and deaths from any cause potentially prevented over a four-year period among participants meeting SELECT trial inclusion criteria. In a sample of n = 216 individuals (corresponding to 4,473,681 adults in the U.S. population) potentially eligible for this therapy, a total of 356,329 MACE and 232,808 all-cause mortality events were expected without semaglutide over 4 years and 35,633 MACE and 22,117 all-cause mortality events would be prevented with 50% uptake of semaglutide. Approximately 4.5 million adults in the U.S. are forecasted to be eligible for semaglutide 2.4mg SC weekly therapy, with substantial impact on CVD and mortality if accessible and broadly used.
doi_str_mv 10.1016/j.ahj.2024.05.007
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3097148681</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0002870324001224</els_id><sourcerecordid>3096044932</sourcerecordid><originalsourceid>FETCH-LOGICAL-c263t-871df9b0222a9f3701fb944986181decd45bcdcaa93c757e22a35b847bae354c3</originalsourceid><addsrcrecordid>eNp9kctO5DAQRa0Ro6Fh5gPYIEts2HTGrzwsVqjVPKSWZgGsLceuNI6SONhJS_w97mlgwYJVqUqnbpXuReiMkowSWvxtM_3cZowwkZE8I6T8gRaUyHJZlEIcoQUhhC2rkvBjdBJjm9qCVcUvdMwlrZjkcoHqlQ7W-Z2OZu50wLCDYcIB7Gwm5wesez9sscZPD3j0Y0L-T6FzW1d3gBsfcIReb7t5chbwCAFPz4Af1pv16hFPwenuN_rZ6C7Cn_d6ip5u1o-ru-Xm3-396nqzNKzgU_qT2kbWhDGmZcNLQptaCiGrglbUgrEir401WktuyryEhPG8rkRZa-C5MPwUXR50x-BfZoiT6l000HV6AD9HxZMzVFRFRRN68QVt_RyG9N2eKkg6y1mi6IEywccYoFFjcL0Or4oStQ9AtSoFoPYBKJKrFEDaOX9Xnuse7OfGh-MJuDoAkKzYOQgqGgeDAesCmElZ776RfwOr55V6</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3096044932</pqid></control><display><type>article</type><title>Cardiovascular event reduction among a US population eligible for semaglutide per the SELECT trial</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><source>ProQuest Central UK/Ireland</source><creator>Lusk, Jay B. ; Glover, LáShauntá ; Soneji, Samir ; Granger, Christopher B. ; O'Brien, Emily ; Pagidipati, Neha</creator><creatorcontrib>Lusk, Jay B. ; Glover, LáShauntá ; Soneji, Samir ; Granger, Christopher B. ; O'Brien, Emily ; Pagidipati, Neha</creatorcontrib><description>Our objective was to determine the number of major cardiovascular events (MACE, nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death) and deaths from any cause that could be prevented across varying nationwide uptake of semaglutide 2.4 mg SC weekly for the secondary prevention of cardiovascular disease. Using a nationally representative cross-sectional study of participants in the 2017-2018 and 2019-March 2020 cycles of the National Health and Nutrition Examination Survey in the U.S. (NHANES), we estimated the number of MACE and deaths from any cause potentially prevented over a four-year period among participants meeting SELECT trial inclusion criteria. In a sample of n = 216 individuals (corresponding to 4,473,681 adults in the U.S. population) potentially eligible for this therapy, a total of 356,329 MACE and 232,808 all-cause mortality events were expected without semaglutide over 4 years and 35,633 MACE and 22,117 all-cause mortality events would be prevented with 50% uptake of semaglutide. Approximately 4.5 million adults in the U.S. are forecasted to be eligible for semaglutide 2.4mg SC weekly therapy, with substantial impact on CVD and mortality if accessible and broadly used.</description><identifier>ISSN: 0002-8703</identifier><identifier>ISSN: 1097-6744</identifier><identifier>EISSN: 1097-6744</identifier><identifier>DOI: 10.1016/j.ahj.2024.05.007</identifier><identifier>PMID: 39182939</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adult ; Adults ; Aged ; Body mass index ; Cardiovascular diseases ; Cardiovascular Diseases - epidemiology ; Cardiovascular Diseases - mortality ; Cardiovascular Diseases - prevention &amp; control ; Cerebral infarction ; Cross-Sectional Studies ; Diabetes ; Drug dosages ; Editing ; Estimates ; Fatalities ; Female ; Glucagon-Like Peptides - administration &amp; dosage ; Glucagon-Like Peptides - therapeutic use ; Humans ; Hypoglycemic Agents - therapeutic use ; Male ; Medicare ; Middle Aged ; Mortality ; Myocardial infarction ; Myocardial Infarction - epidemiology ; Myocardial Infarction - prevention &amp; control ; Nutrition Surveys ; Obesity ; Pharmaceuticals ; Secondary Prevention - methods ; Stroke ; Stroke - epidemiology ; Stroke - prevention &amp; control ; United States - epidemiology</subject><ispartof>The American heart journal, 2024-10, Vol.276, p.110-114</ispartof><rights>2024 Elsevier Inc.</rights><rights>Copyright © 2024 Elsevier Inc. All rights reserved.</rights><rights>2024. Elsevier Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c263t-871df9b0222a9f3701fb944986181decd45bcdcaa93c757e22a35b847bae354c3</cites><orcidid>0000-0002-5004-8868</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/3096044932?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>315,781,785,3551,27929,27930,46000,64390,64392,64394,72474</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39182939$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lusk, Jay B.</creatorcontrib><creatorcontrib>Glover, LáShauntá</creatorcontrib><creatorcontrib>Soneji, Samir</creatorcontrib><creatorcontrib>Granger, Christopher B.</creatorcontrib><creatorcontrib>O'Brien, Emily</creatorcontrib><creatorcontrib>Pagidipati, Neha</creatorcontrib><title>Cardiovascular event reduction among a US population eligible for semaglutide per the SELECT trial</title><title>The American heart journal</title><addtitle>Am Heart J</addtitle><description>Our objective was to determine the number of major cardiovascular events (MACE, nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death) and deaths from any cause that could be prevented across varying nationwide uptake of semaglutide 2.4 mg SC weekly for the secondary prevention of cardiovascular disease. Using a nationally representative cross-sectional study of participants in the 2017-2018 and 2019-March 2020 cycles of the National Health and Nutrition Examination Survey in the U.S. (NHANES), we estimated the number of MACE and deaths from any cause potentially prevented over a four-year period among participants meeting SELECT trial inclusion criteria. In a sample of n = 216 individuals (corresponding to 4,473,681 adults in the U.S. population) potentially eligible for this therapy, a total of 356,329 MACE and 232,808 all-cause mortality events were expected without semaglutide over 4 years and 35,633 MACE and 22,117 all-cause mortality events would be prevented with 50% uptake of semaglutide. Approximately 4.5 million adults in the U.S. are forecasted to be eligible for semaglutide 2.4mg SC weekly therapy, with substantial impact on CVD and mortality if accessible and broadly used.</description><subject>Adult</subject><subject>Adults</subject><subject>Aged</subject><subject>Body mass index</subject><subject>Cardiovascular diseases</subject><subject>Cardiovascular Diseases - epidemiology</subject><subject>Cardiovascular Diseases - mortality</subject><subject>Cardiovascular Diseases - prevention &amp; control</subject><subject>Cerebral infarction</subject><subject>Cross-Sectional Studies</subject><subject>Diabetes</subject><subject>Drug dosages</subject><subject>Editing</subject><subject>Estimates</subject><subject>Fatalities</subject><subject>Female</subject><subject>Glucagon-Like Peptides - administration &amp; dosage</subject><subject>Glucagon-Like Peptides - therapeutic use</subject><subject>Humans</subject><subject>Hypoglycemic Agents - therapeutic use</subject><subject>Male</subject><subject>Medicare</subject><subject>Middle Aged</subject><subject>Mortality</subject><subject>Myocardial infarction</subject><subject>Myocardial Infarction - epidemiology</subject><subject>Myocardial Infarction - prevention &amp; control</subject><subject>Nutrition Surveys</subject><subject>Obesity</subject><subject>Pharmaceuticals</subject><subject>Secondary Prevention - methods</subject><subject>Stroke</subject><subject>Stroke - epidemiology</subject><subject>Stroke - prevention &amp; control</subject><subject>United States - epidemiology</subject><issn>0002-8703</issn><issn>1097-6744</issn><issn>1097-6744</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp9kctO5DAQRa0Ro6Fh5gPYIEts2HTGrzwsVqjVPKSWZgGsLceuNI6SONhJS_w97mlgwYJVqUqnbpXuReiMkowSWvxtM_3cZowwkZE8I6T8gRaUyHJZlEIcoQUhhC2rkvBjdBJjm9qCVcUvdMwlrZjkcoHqlQ7W-Z2OZu50wLCDYcIB7Gwm5wesez9sscZPD3j0Y0L-T6FzW1d3gBsfcIReb7t5chbwCAFPz4Af1pv16hFPwenuN_rZ6C7Cn_d6ip5u1o-ru-Xm3-396nqzNKzgU_qT2kbWhDGmZcNLQptaCiGrglbUgrEir401WktuyryEhPG8rkRZa-C5MPwUXR50x-BfZoiT6l000HV6AD9HxZMzVFRFRRN68QVt_RyG9N2eKkg6y1mi6IEywccYoFFjcL0Or4oStQ9AtSoFoPYBKJKrFEDaOX9Xnuse7OfGh-MJuDoAkKzYOQgqGgeDAesCmElZ776RfwOr55V6</recordid><startdate>202410</startdate><enddate>202410</enddate><creator>Lusk, Jay B.</creator><creator>Glover, LáShauntá</creator><creator>Soneji, Samir</creator><creator>Granger, Christopher B.</creator><creator>O'Brien, Emily</creator><creator>Pagidipati, Neha</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7RV</scope><scope>7TS</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-5004-8868</orcidid></search><sort><creationdate>202410</creationdate><title>Cardiovascular event reduction among a US population eligible for semaglutide per the SELECT trial</title><author>Lusk, Jay B. ; Glover, LáShauntá ; Soneji, Samir ; Granger, Christopher B. ; O'Brien, Emily ; Pagidipati, Neha</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c263t-871df9b0222a9f3701fb944986181decd45bcdcaa93c757e22a35b847bae354c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Adult</topic><topic>Adults</topic><topic>Aged</topic><topic>Body mass index</topic><topic>Cardiovascular diseases</topic><topic>Cardiovascular Diseases - epidemiology</topic><topic>Cardiovascular Diseases - mortality</topic><topic>Cardiovascular Diseases - prevention &amp; control</topic><topic>Cerebral infarction</topic><topic>Cross-Sectional Studies</topic><topic>Diabetes</topic><topic>Drug dosages</topic><topic>Editing</topic><topic>Estimates</topic><topic>Fatalities</topic><topic>Female</topic><topic>Glucagon-Like Peptides - administration &amp; dosage</topic><topic>Glucagon-Like Peptides - therapeutic use</topic><topic>Humans</topic><topic>Hypoglycemic Agents - therapeutic use</topic><topic>Male</topic><topic>Medicare</topic><topic>Middle Aged</topic><topic>Mortality</topic><topic>Myocardial infarction</topic><topic>Myocardial Infarction - epidemiology</topic><topic>Myocardial Infarction - prevention &amp; control</topic><topic>Nutrition Surveys</topic><topic>Obesity</topic><topic>Pharmaceuticals</topic><topic>Secondary Prevention - methods</topic><topic>Stroke</topic><topic>Stroke - epidemiology</topic><topic>Stroke - prevention &amp; control</topic><topic>United States - epidemiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lusk, Jay B.</creatorcontrib><creatorcontrib>Glover, LáShauntá</creatorcontrib><creatorcontrib>Soneji, Samir</creatorcontrib><creatorcontrib>Granger, Christopher B.</creatorcontrib><creatorcontrib>O'Brien, Emily</creatorcontrib><creatorcontrib>Pagidipati, Neha</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Physical Education Index</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>The American heart journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lusk, Jay B.</au><au>Glover, LáShauntá</au><au>Soneji, Samir</au><au>Granger, Christopher B.</au><au>O'Brien, Emily</au><au>Pagidipati, Neha</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cardiovascular event reduction among a US population eligible for semaglutide per the SELECT trial</atitle><jtitle>The American heart journal</jtitle><addtitle>Am Heart J</addtitle><date>2024-10</date><risdate>2024</risdate><volume>276</volume><spage>110</spage><epage>114</epage><pages>110-114</pages><issn>0002-8703</issn><issn>1097-6744</issn><eissn>1097-6744</eissn><abstract>Our objective was to determine the number of major cardiovascular events (MACE, nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death) and deaths from any cause that could be prevented across varying nationwide uptake of semaglutide 2.4 mg SC weekly for the secondary prevention of cardiovascular disease. Using a nationally representative cross-sectional study of participants in the 2017-2018 and 2019-March 2020 cycles of the National Health and Nutrition Examination Survey in the U.S. (NHANES), we estimated the number of MACE and deaths from any cause potentially prevented over a four-year period among participants meeting SELECT trial inclusion criteria. In a sample of n = 216 individuals (corresponding to 4,473,681 adults in the U.S. population) potentially eligible for this therapy, a total of 356,329 MACE and 232,808 all-cause mortality events were expected without semaglutide over 4 years and 35,633 MACE and 22,117 all-cause mortality events would be prevented with 50% uptake of semaglutide. Approximately 4.5 million adults in the U.S. are forecasted to be eligible for semaglutide 2.4mg SC weekly therapy, with substantial impact on CVD and mortality if accessible and broadly used.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>39182939</pmid><doi>10.1016/j.ahj.2024.05.007</doi><tpages>5</tpages><orcidid>https://orcid.org/0000-0002-5004-8868</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0002-8703
ispartof The American heart journal, 2024-10, Vol.276, p.110-114
issn 0002-8703
1097-6744
1097-6744
language eng
recordid cdi_proquest_miscellaneous_3097148681
source MEDLINE; Access via ScienceDirect (Elsevier); ProQuest Central UK/Ireland
subjects Adult
Adults
Aged
Body mass index
Cardiovascular diseases
Cardiovascular Diseases - epidemiology
Cardiovascular Diseases - mortality
Cardiovascular Diseases - prevention & control
Cerebral infarction
Cross-Sectional Studies
Diabetes
Drug dosages
Editing
Estimates
Fatalities
Female
Glucagon-Like Peptides - administration & dosage
Glucagon-Like Peptides - therapeutic use
Humans
Hypoglycemic Agents - therapeutic use
Male
Medicare
Middle Aged
Mortality
Myocardial infarction
Myocardial Infarction - epidemiology
Myocardial Infarction - prevention & control
Nutrition Surveys
Obesity
Pharmaceuticals
Secondary Prevention - methods
Stroke
Stroke - epidemiology
Stroke - prevention & control
United States - epidemiology
title Cardiovascular event reduction among a US population eligible for semaglutide per the SELECT trial
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-14T21%3A15%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cardiovascular%20event%20reduction%20among%20a%20US%20population%20eligible%20for%20semaglutide%20per%20the%20SELECT%20trial&rft.jtitle=The%20American%20heart%20journal&rft.au=Lusk,%20Jay%20B.&rft.date=2024-10&rft.volume=276&rft.spage=110&rft.epage=114&rft.pages=110-114&rft.issn=0002-8703&rft.eissn=1097-6744&rft_id=info:doi/10.1016/j.ahj.2024.05.007&rft_dat=%3Cproquest_cross%3E3096044932%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3096044932&rft_id=info:pmid/39182939&rft_els_id=S0002870324001224&rfr_iscdi=true